{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:58:54Z","timestamp":1785275934901,"version":"3.55.0"},"reference-count":273,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1053\/j.jvca.2025.12.003","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:28:02Z","timestamp":1764980882000},"page":"960-984","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in Cardiovascular Pharmacotherapy. VI. Sacubitril-Valsartan, An Angiotensin Receptor-Neprilysin Inhibitor"],"prefix":"10.1053","volume":"40","author":[{"given":"Paul S.","family":"Pagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie K.","family":"Freed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2025.12.003_bib0001","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0024-3205(81)90370-2","article-title":"A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats","volume":"28","author":"de Bold","year":"1981","journal-title":"Life Sci"},{"key":"10.1053\/j.jvca.2025.12.003_bib0002","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0006-291X(83)91675-3","article-title":"The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties","volume":"117","author":"Flynn","year":"1983","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1053\/j.jvca.2025.12.003_bib0003","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1073\/pnas.81.9.2640","article-title":"Amino acid sequence of rat atrial peptides: Natriuretic activity of native and synthetic forms","volume":"81","author":"Seidah","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.jvca.2025.12.003_bib0004","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1126\/science.6419347","article-title":"Purification and sequence analysis of bioactive atrial peptides (atriopeptins)","volume":"223","author":"Currie","year":"1984","journal-title":"Science"},{"key":"10.1053\/j.jvca.2025.12.003_bib0005","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0006-291X(84)91077-5","article-title":"Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP)","volume":"118","author":"Kangawa","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1053\/j.jvca.2025.12.003_bib0006","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0006-291X(84)80203-X","article-title":"Isolation and sequence determination of peptide components of atrial natriuretic factor","volume":"120","author":"Napier","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1053\/j.jvca.2025.12.003_bib0007","doi-asserted-by":"crossref","first-page":"5946","DOI":"10.1073\/pnas.81.19.5946","article-title":"Specific membrane receptors for atrial natriuretic factor in renal and vascular tissues","volume":"81","author":"Napier","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.jvca.2025.12.003_bib0008","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1126\/science.2935937","article-title":"Atrial natriuretic peptide elevation in congestive heart failure in the human","volume":"231","author":"Burnett","year":"1986","journal-title":"Science"},{"key":"10.1053\/j.jvca.2025.12.003_bib0009","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF02125838","article-title":"Atrial natriuretic factor: Physiologic actions and implications in congestive heart failure","volume":"1","author":"Edwards","year":"1987","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1053\/j.jvca.2025.12.003_bib0010","first-page":"55","article-title":"Significance of atrial natriuretic factor in chronic heart failure","volume":"40","author":"McMurray","year":"1988","journal-title":"Br J Hosp Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0011","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.HYP.8.4.312","article-title":"Cardiovascular effects of atrial natriuretic factor in anesthetized and conscious dogs","volume":"8","author":"Kleinert","year":"1986","journal-title":"Hypertension"},{"key":"10.1053\/j.jvca.2025.12.003_bib0012","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/332078a0","article-title":"A new natriuretic peptide in porcine brain","volume":"332","author":"Sudoh","year":"1988","journal-title":"Nature"},{"key":"10.1053\/j.jvca.2025.12.003_bib0013","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/0006-291X(90)92401-K","article-title":"C-type natriuretic peptide (CNP): A new member of natriuretic peptide family identified in porcine brain","volume":"168","author":"Sudoh","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1053\/j.jvca.2025.12.003_bib0014","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1210\/endo-129-2-1104","article-title":"C-type natriuretic peptide (CNP) in rats and humans","volume":"129","author":"Komatsu","year":"1991","journal-title":"Endocrinology"},{"key":"10.1053\/j.jvca.2025.12.003_bib0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1042\/bj1340043","article-title":"Studies on the enzymology of purified preparations of brush border from rabbit kidney","volume":"134","author":"George","year":"1973","journal-title":"Biochem J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0016","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1042\/bj1370477","article-title":"The purification and specificity of a neutral endopeptidase from rabbit kidney brush border","volume":"137","author":"Kerr","year":"1974","journal-title":"Biochem J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0017","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1042\/bj1370489","article-title":"The molecular weight and properties of a neutral metallo-endopeptidase from rabbit kidney brush border","volume":"137","author":"Kerr","year":"1974","journal-title":"Biochem J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0018","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJM199807303390507","article-title":"Natriuretic peptides","volume":"339","author":"Levin","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0019","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ejhf.250","article-title":"Neprilysin inhibition to treat heart failure: A tale of science, serendipity, and second chances","volume":"17","author":"McMurray","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0020","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacbts.2022.05.010","article-title":"Neprilysin inhibitors in heart failure. The science, mechanisms of action, clinical studies, and unanswered questions","volume":"8","author":"Bozkurt","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"10.1053\/j.jvca.2025.12.003_bib0021","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/eurheartj\/ehac759","article-title":"Endocrine functions of the heart: From bench to bedside","volume":"44","author":"Volpe","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0022","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0023","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/eurheartj\/eht466","article-title":"Natriuretic peptides in cardiovascular diseases: Current use and perspectives","volume":"35","author":"Volpe","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0024","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41569-020-0381-0","article-title":"Cardiac natriuretic peptides","volume":"17","author":"Goetze","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0025","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jacc.2016.04.060","article-title":"A test in context: Neprilysin. Function, inhibition, and biomarker","volume":"68","author":"Bayes-Genis","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0026","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/cvr\/28.10.1519","article-title":"Selective changes in natriuretic peptide and early response gene expression in isolated rat atria following stimulation by stretch or endothelin-1","volume":"28","author":"Bruneau","year":"1994","journal-title":"Cardiovasc Res"},{"key":"10.1053\/j.jvca.2025.12.003_bib0027","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1161\/01.CIR.87.1.192","article-title":"Angiotensin II directly stimulates release of atrial natriuretic factor in isolated rabbit hearts","volume":"87","author":"Focaccio","year":"1993","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0028","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3390\/jcm8101746","article-title":"The endocrine function of the heart: Physiology and involvements of natriuretic peptides and cyclic nucleotide phosphodiesterases in heart failure","volume":"8","author":"Lugnier","year":"2019","journal-title":"J Clin Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0029","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1210\/er.2005-0014","article-title":"Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions","volume":"27","author":"Potter","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1053\/j.jvca.2025.12.003_bib0030","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/0024-3205(90)90208-9","article-title":"Degradation and clearance of atrial natriuretic peptide (ANF)","volume":"47","author":"Gerbes","year":"1990","journal-title":"Life Sci"},{"key":"10.1053\/j.jvca.2025.12.003_bib0031","first-page":"R373","article-title":"Clearance receptors and endopeptidase 24.11: Equal role in natriuretic peptide metabolism in conscious sheep","volume":"271","author":"Charles","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0032","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1742-4658.2011.08082.x","article-title":"Natriuretic peptide metabolism, clearance, and degradation","volume":"278","author":"Potter","year":"2011","journal-title":"FEBS J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0033","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1126\/science.2823385","article-title":"Physiological role of silent receptors of atrial natriuretic factor","volume":"238","author":"Maack","year":"1987","journal-title":"Science"},{"key":"10.1053\/j.jvca.2025.12.003_bib0034","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1073\/pnas.86.18.7103","article-title":"Organization of the gene encoding common acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): Multiple miniexons and separate 5\u2019 untranslated regions","volume":"86","author":"D\u2019Adamio","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.jvca.2025.12.003_bib0035","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0021-9258(18)52423-6","article-title":"Evidence that both arginine 102 and arginine 747 are involved in substrate binding to neutral endopeptidase (EC 3.4.24.11)","volume":"266","author":"Beaumont","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1053\/j.jvca.2025.12.003_bib0036","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0031-6997(25)00449-1","article-title":"Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology","volume":"45","author":"Roques","year":"1993","journal-title":"Pharmacol Rev"},{"key":"10.1053\/j.jvca.2025.12.003_bib0037","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jacc.2014.11.048","article-title":"Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients","volume":"65","author":"Bayes-Genis","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0038","unstructured":"BRENDA. Information on EC 3.4.24.11\u2014Neprilysin. https:\/\/www.brenda-enzymes.org\/enzyme.php?ecno=3.4.24.11. Published 2025. Accessed September 26, 2025."},{"key":"10.1053\/j.jvca.2025.12.003_bib0039","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jmb.2009.08.025","article-title":"Structural substrate conditions required for neutral endopeptidase-mediated natriuretic peptide degradation","volume":"393","author":"Pankow","year":"2009","journal-title":"J Mol Biol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0040","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1677\/joe.0.1670239","article-title":"Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase","volume":"167","author":"Smith","year":"2000","journal-title":"J Endocrinol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0041","doi-asserted-by":"crossref","first-page":"7580","DOI":"10.1073\/pnas.86.19.7580","article-title":"Protection of atrial natriuretic factor against degradation: Diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan","volume":"86","author":"Gros","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.jvca.2025.12.003_bib0042","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(89)90714-9","article-title":"Effects of UK 69578: A novel atriopeptidase inhibitor","volume":"2","author":"Northridge","year":"1989","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2025.12.003_bib0043","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/0140-6736(90)90595-V","article-title":"Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure","volume":"335","author":"Kahn","year":"1990","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2025.12.003_bib0044","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/01.CIR.97.23.2323","article-title":"Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo","volume":"97","author":"Ferro","year":"1998","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0045","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/01.RES.71.6.1501","article-title":"Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers","volume":"71","author":"Richards","year":"1992","journal-title":"Circ Res"},{"key":"10.1053\/j.jvca.2025.12.003_bib0046","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00004872-199207000-00002","article-title":"Candoxatril, a neutral endopeptidase inhibitor: Efficacy and tolerability in essential hypertension","volume":"10","author":"Bevan","year":"1992","journal-title":"J Hypertens"},{"key":"10.1053\/j.jvca.2025.12.003_bib0047","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/01.CIR.86.4.1089","article-title":"Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure","volume":"86","author":"Munzel","year":"1992","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0048","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s002280050196","article-title":"Neutral endopeptidase 24.11 inhibition may not exhibit beneficial hemodynamic effects in patients with congestive heart failure","volume":"51","author":"Kentsch","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0049","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(05)77712-6","article-title":"Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators","volume":"351","author":"Cleland","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2025.12.003_bib0050","first-page":"S37","article-title":"Vasopeptidase inhibition: A new concept in blood pressure management","volume":"17","author":"Burnett","year":"1999","journal-title":"J Hypertens"},{"key":"10.1053\/j.jvca.2025.12.003_bib0051","first-page":"266","article-title":"Omapatrilat: A unique new agent for the treatment of cardiovascular disease","volume":"2","author":"Nawarskas","year":"2000","journal-title":"Heart Dis"},{"key":"10.1053\/j.jvca.2025.12.003_bib0052","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1053\/euhj.1998.1201","article-title":"Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition","volume":"19","author":"Newby","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0053","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","article-title":"Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patient with heart failure: IMPRESS randomised trial","volume":"356","author":"Rouleau","year":"2000","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2025.12.003_bib0054","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1161\/01.CIR.0000020500.77568.3C","article-title":"Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: Results of the conduit hemodynamics of omapatrilat international research study","volume":"105","author":"Mitchell","year":"2002","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: The omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.jvca.2025.12.003_bib0056","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0057","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/01.HYP.0000054215.71691.16","article-title":"Vasopeptidase inhibition: A double-edged sword?","volume":"41","author":"Campell","year":"2003","journal-title":"Hypertension"},{"key":"10.1053\/j.jvca.2025.12.003_bib0058","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjmed.2014.07.011","article-title":"Angiotensin-converting enzyme inhibitor-induced angioedema","volume":"128","author":"Bezalel","year":"2015","journal-title":"Am J Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0059","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjp.0707641","article-title":"Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: Rank efficacy of enzymes associated with bradykinin-mediated angioedema","volume":"153","author":"Fryer","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411649","article-title":"Bradykinin metabolism and drug-induced angioedema","volume":"24","author":"Smolinska","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.jvca.2025.12.003_bib0061","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.tetlet.2011.11.029","article-title":"LCZ696: A dual-acting sodium supramolecular complex","volume":"53","author":"Feng","year":"2012","journal-title":"Tetrahedron Letters"},{"key":"10.1053\/j.jvca.2025.12.003_bib0062","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1021\/jm00010a014","article-title":"Dicarboxylic acid dipeptide neutral endopeptidase inhibitors","volume":"38","author":"Ksander","year":"1995","journal-title":"J Med Chem"},{"key":"10.1053\/j.jvca.2025.12.003_bib0063","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0064","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/FJC.0b013e318210fc7e","article-title":"Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat","volume":"57","author":"Hegde","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0065","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2025.12.003_bib0066","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/archinte.164.8.910","article-title":"Angioedema associated with angiotensin-converting enzyme inhibitor use: Outcome after switching to a different treatment","volume":"164","author":"Cicardi","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0067","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1159\/000507327","article-title":"Effects of LCZ696 (sacubitril\/valsartan) on blood pressure in patients with hypertension: A meta-analysis of randomized controlled trials","volume":"145","author":"Geng","year":"2020","journal-title":"Cardiology"},{"key":"10.1053\/j.jvca.2025.12.003_bib0068","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","volume":"15","author":"McMurray","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0069","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/ejhf.115","article-title":"Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)","volume":"16","author":"McMurray","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0070","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0071","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ejhf.548","article-title":"Initiating sacubitril\/valsartan (LCZ696) in heart failure: Results of TITRATION, a double-blind, randomized comparison of two uptitration regimens","volume":"18","author":"Senni","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0072","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0073","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0074","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0075","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ehf2.14857","article-title":"2024 update in heart failure","volume":"12","author":"Beghini","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0076","first-page":"330","article-title":"Entresto (sacubitril\/valsartan): First-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure","volume":"8","author":"Fala","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1053\/j.jvca.2025.12.003_bib0077","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jjcc.2016.11.011","article-title":"Efficacy and safety of sacubitril\/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study","volume":"70","author":"Tsutsui","year":"2017","journal-title":"J Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0078","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1253\/circj.CJ-17-1424","article-title":"Angiotensin receptor neprilysin inhibitor in Japanese patients with heart failure and reduced ejection fraction\u2014Baseline characteristics and treatment of PARALLEL-HF trial","volume":"82","author":"Tsutsui","year":"2018","journal-title":"Circ J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0079","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1253\/circj.CJ-20-0854","article-title":"Efficacy and safety of sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction\u2014Results from the PARALLEL-HF study","volume":"85","author":"Tsutsui","year":"2021","journal-title":"Circ J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0080","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/phar.2075","article-title":"PARADIGM-HF trial: Secondary analyses address unanswered questions","volume":"38","author":"Smith","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.jvca.2025.12.003_bib0081","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jchf.2020.06.020","article-title":"Sacubitril\/valsartan: Neprilysin inhibition 5 years after PARADIGM-HF","volume":"8","author":"Docherty","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0082","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/eurheartj\/ehu455","article-title":"A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure","volume":"36","author":"McMurray","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0083","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1161\/CIRCULATIONAHA.119.039920","article-title":"Prognostic implication of congestion on physical examination among contemporary patients with heart failure and reduced ejection fraction: PARADIGM-HF","volume":"140","author":"Selvaraj","year":"2019","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0084","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0085","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0086","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/ejhf.2419","article-title":"Effect of sacubitril\/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF","volume":"24","author":"Curtain","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0087","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jacc.2016.04.047","article-title":"Influence of sacubitril\/valsartan (LCZ696) on 30-day readmission after heart failure hospitalization","volume":"68","author":"Desai","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0088","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamacardio.2024.2566","article-title":"Effects of sacubitril\/valsartan on all-cause hospitalizations in heart failure: Post hoc analysis of the PARADIGM-HF and PARAGON-HF randomized clinical trials","volume":"9","author":"Lu","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0089","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","article-title":"Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: Insights from PARADIGM-HF","volume":"36","author":"Jhund","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0090","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.038249","article-title":"Comprehensive analysis of the effects of sacubitril\/valsartan according to sex among patients with heart failure and reduced ejection fraction in PARADIGM-HF","volume":"14","author":"Chimura","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2025.12.003_bib0091","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jchf.2024.08.008","article-title":"Race in heart failure: A pooled participant-level analysis of the global PARADIGM-HF and PARAGON-HF trials","volume":"13","author":"Lu","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0092","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1093\/eurheartj\/ehw226","article-title":"Geographic variations in the PARADIGM-HF heart failure trial","volume":"37","author":"Kristensen","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0093","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ejhf.3515","article-title":"Effects of sacubitril\/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF","volume":"27","author":"Gupta","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0094","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jchf.2019.02.015","article-title":"Outcomes and effects of treatment according to etiology of HFrEF: An analysis of PARADIGM-HF","volume":"7","author":"Balmforth","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0095","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002744","volume":"9","author":"Solomon","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0096","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jchf.2024.12.010","article-title":"Effects of sacubitril\/valsartan according to natriuretic peptide levels in patients enrolled in PARADIGM-HF and PARAGON-HF","volume":"13","author":"Kondo","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0097","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002560","article-title":"Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: Insights from Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial","volume":"9","author":"Kristensen","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0098","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jchf.2022.12.012","article-title":"Prevalent and incident anemia in PARADIGM-HF and the effect of sacubitril\/valsartan","volume":"11","author":"Curtain","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0099","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019238","article-title":"Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: Insights from PARADIGM-HF","volume":"10","author":"Ehteshami-Afshar","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2025.12.003_bib0100","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jchf.2016.05.002","article-title":"Efficacy of sacubitril\/valsartan relative to a prior decompensation: The PARADIGM-HF trial","volume":"4","author":"Solomon","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0101","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jacc.2015.08.878","article-title":"Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: An analysis of mortality and morbidity in PARADIGM-HF","volume":"66","author":"Simpson","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0102","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.jacc.2024.03.392","article-title":"Effects of sacubitril\/valsartan across the spectrum of renal impairment in patients with heart failure","volume":"83","author":"Chatur","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0103","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/ejhf.2421","article-title":"Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure","volume":"24","author":"McCausland","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0104","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.jchf.2024.03.014","article-title":"Sacubitril\/valsartan in patients with Heart Failure and deterioration in eGFR to <30 mL\/min\/1.73 m2","volume":"12","author":"Chatur","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: A post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0106","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: A secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0107","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003430","article-title":"Health-related quality of life outcomes in PARADIGM-HF","volume":"10","author":"Lewis","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0108","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/ehjcvp\/pvaf064","article-title":"Sacubitril\/valsartan and quality of life assessed using the EuroQol 5-dimension 3-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF\/HFpEF","volume":"11","author":"Yang","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1053\/j.jvca.2025.12.003_bib0109","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1161\/CIRCULATIONAHA.115.020729","article-title":"Importance of clinical worsening of heart failure treated in the outpatient setting: Evidence from the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF)","volume":"133","author":"Okumura","year":"2016","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0110","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ejhf.1402","article-title":"Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: The PARADIGM-HF trial","volume":"21","author":"Vardeny","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0111","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","article-title":"Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF","volume":"38","author":"Bohm","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0112","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004745","volume":"11","author":"Vardeny","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0113","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.jacc.2024.08.012","article-title":"Asymptomatic vs symptomatic hypotension with sacubitril\/valsartan in heart failure and reduced ejection fraction in PARADIGM-HF","volume":"84","author":"Matsumoto","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0114","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrcardio.2016.200","article-title":"Long-term neprilysin inhibition\u2014Implications for ARNIs","volume":"14","author":"Campbell","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0115","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40256-020-00445-7","article-title":"Effect of sacubitril\/valsartan on neurocognitive function: Current status and future directions","volume":"21","author":"Galo","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1053\/j.jvca.2025.12.003_bib0116","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ejhf.687","article-title":"Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction","volume":"19","author":"Cannon","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0117","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100372","article-title":"Sacubitril\/valsartan and cognitive outcomes in heart failure with reduced ejection fraction","volume":"2","author":"Grewal","year":"2023","journal-title":"JACC Adv"},{"key":"10.1053\/j.jvca.2025.12.003_bib0118","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100388","article-title":"Sacubitril\/valsartan and cognitive outcomes in heart failure with reduced ejection: A new pharmacological indication?","volume":"2","author":"Correale","year":"2023","journal-title":"JACC Adv"},{"key":"10.1053\/j.jvca.2025.12.003_bib0119","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.17993","article-title":"Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective","volume":"28","author":"Ali","year":"2024","journal-title":"J Cell Mol Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0120","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13195-024-01547-z","article-title":"Association between treatment with sacubitril\/valsartan and the risk of Alzheimer\u2019s disease: A clinical update","volume":"16","author":"Garnier-Crussard","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"10.1053\/j.jvca.2025.12.003_bib0121","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jacc.2019.01.018","article-title":"B-type natriuretic peptide during treatment with sacubitril\/valsartan: The PARADIGM-HF trial","volume":"73","author":"Myhre","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0122","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijcard.2021.01.061","article-title":"Real-world effectiveness and safety of sacubitril valsartan in heart failure: A systematic review","volume":"331","author":"Proudfoot","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0123","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/ehf2.15183","article-title":"Real-world comparative effectiveness of sacubitril\/valsartan versus RAS inhibition alone in patients with de novo heart failure","volume":"12","author":"Bhatt","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0124","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.3390\/jcm12196247","article-title":"The long-term benefit of sacubitril\/valsartan in patients with HFrEF: A 5-year follow-up study in a real world population","volume":"12","author":"Dattilo","year":"2023","journal-title":"J Clin Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0125","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/ejhf.3634","article-title":"Safety and tolerability of sacubitril\/valsartan in chronic heart failure and reduced ejection fraction: Results from the open-label extension of the PARADIGM-HF study","volume":"27","author":"Senni","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0126","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction","volume":"1","author":"Gaziano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0127","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0128","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jchf.2020.05.005","article-title":"Sacubitril\/valsartan in advanced heart failure with reduced ejection fraction: Rationale and design of the LIFE trial","volume":"8","author":"Mann","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0129","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with sacubitril\/valsartan in patients with advanced heart failure and reduced ejection fraction: A randomized clinical trial","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2018.01.004","article-title":"Rationale and design of the Comparison of Sacubitril\/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode (PIONEER-HF) trial","volume":"198","author":"Velazquez","year":"2018","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0131","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0132","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jchf.2020.06.008","article-title":"Efficacy and safety of sacubitril\/valsartan by dose level achieved in the PIONEER-HF trial","volume":"8","author":"Berg","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0133","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2024.01.027","article-title":"Sacubitril\/valsartan in patients hospitalized with decompensated heart failure","volume":"83","author":"Morrow","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0134","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.jacc.2020.06.073","article-title":"Angiotensin receptor-neprilysin inhibition based on history of heart failure and use of renin-angiotensin system antagonists","volume":"76","author":"Ambrosy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0135","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jchf.2020.06.019","article-title":"Angiotensin-neprilysin inhibition in black Americans: Data from the PIONEER-HF trial","volume":"8","author":"Berardi","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0136","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1093\/eurheartj\/ehae561","article-title":"In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: The PREMIER trial","volume":"45","author":"Tanaka","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0137","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007034","article-title":"Efficacy and safety of sacubitril\/valsartan in high-risk patients in the PIONEER-HF trial","volume":"14","author":"Berg","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0138","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIRCULATIONAHA.117.031560","article-title":"Prognostic value of high-sensitivity troponin T in chronic heart failure: An individual patient data meta-analysis","volume":"137","author":"Aimo","year":"2018","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0139","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cca.2020.04.011","article-title":"Soluble ST2: A complex and diverse role in several diseases","volume":"507","author":"Homsak","year":"2020","journal-title":"Clin Chim Acta"},{"key":"10.1053\/j.jvca.2025.12.003_bib0140","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.ijcard.2013.01.228","article-title":"Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study","volume":"168","author":"Lassus","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0141","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMra0800239","article-title":"Biomarkers in heart failure","volume":"358","author":"Braunwald","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0142","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1093\/eurheartj\/ehz240","article-title":"Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial","volume":"40","author":"Morrow","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0143","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamacardio.2019.4665","article-title":"Initiation of angiotensin-neprilysin inhibition after acute decompensated heart failure: Secondary analysis of the open-label extension of the PIONEER-HF trial","volume":"5","author":"DeVore","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0144","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006645","article-title":"Representativeness of the PIONEER-HF clinical trial population in patients hospitalized with heart failure and reduced ejection fraction","volume":"13","author":"Fudim","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0145","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamacardio.2024.3815","article-title":"Angiotensin receptor-neprilysin inhibitor prescribing patterns in patients hospitalized for heart failure","volume":"10","author":"Srivastava","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10741-021-10115-8","article-title":"Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: An expert consensus position paper","volume":"27","author":"Ntalianis","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1053\/j.jvca.2025.12.003_bib0147","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2025.12.003_bib0148","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: Rationale and design of the PARAGON-HF trial","volume":"5","author":"Solomon","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0149","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.004962","article-title":"Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial","volume":"11","author":"Solomon","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0150","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0151","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: Insights from PARAGON-HF","volume":"141","author":"McMurray","year":"2020","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0152","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0153","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2020.02.009","article-title":"Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril\/valsartan","volume":"75","author":"Selvaraj","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0154","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","article-title":"Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction","volume":"42","author":"Jackson","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0155","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.jacc.2024.02.035","article-title":"Sacubitril\/valsartan-related hypotension in patients with heart failure and preserved or mildly reduced ejection fraction","volume":"83","author":"Foa","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0156","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1161\/HYPERTENSIONAHA.120.16277","article-title":"Pulse pressure, prognosis, and influence of sacubitril\/valsartan in heart failure with preserved ejection fraction","volume":"77","author":"Suzuki","year":"2021","journal-title":"Hypertension"},{"key":"10.1053\/j.jvca.2025.12.003_bib0157","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction","volume":"142","author":"McCausland","year":"2020","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0158","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/ejhf.2450","article-title":"Effect of sacubitril\/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: Insights from PARAGON-HF","volume":"24","author":"Peikert","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0159","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jchf.2024.08.022","article-title":"Angiotensin receptor neprilysin inhibition and cardiovascular outcomes across the kidney function spectrum: The PARAGON-HF trial","volume":"13","author":"McCausland","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0160","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/ejhf.3304","article-title":"Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril\/valsartan in PARAGON-HF","volume":"26","author":"Lassen","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0161","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12933-022-01545-1","article-title":"Effects of sacubitril\/valsartan on glycemia in patients with diabetes and heart failure: The PARAGON-HF and PARADIGM-HF trials","volume":"21","author":"Wijkman","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0162","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jacc.2022.06.037","article-title":"Sacubitril\/valsartan and frailty in patients with heart failure and preserved ejection fraction","volume":"80","author":"Butt","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0163","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/ejhf.2738","article-title":"Health-related quality of life outcomes in PARAGON-HF","volume":"24","author":"Chandra","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0164","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ejhf.3535","article-title":"Effect of sacubitril\/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON-HF","volume":"27","author":"Wang","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0165","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.cardfail.2023.05.003","article-title":"Duration of heart failure with preserved ejection fraction and outcomes with sacubitril\/valsartan: Insights from the PARAGON-HF trial","volume":"29","author":"Ostrominski","year":"2023","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0166","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jacc.2019.11.003","article-title":"Prior heart failure hospitalization, clinical outcomes, and response to sacubitril\/valsartan compared with valsartan in HFpEF","volume":"75","author":"Vaduganathan","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0167","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jchf.2020.03.002","article-title":"Effects of sacubitril\/valsartan on N-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction","volume":"8","author":"Cunningham","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0168","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jchf.2021.04.009","article-title":"Integrating high-sensitivity troponin T and sacubitril\/valsartan treatment in HFpEF: The PARAGON-HF trial","volume":"9","author":"Gori","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0169","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1002\/ejhf.1984","article-title":"Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF","volume":"22","author":"Selvaraj","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0170","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jacc.2020.05.072","article-title":"Effect of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF","volume":"76","author":"Cunningham","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0171","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ejhf.3414","article-title":"Sacubitril\/valsartan reduces incident anemia and iron therapy utilization in heart failure: The PARAGON-HF trial","volume":"27","author":"Lu","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0172","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ejhf.2703","article-title":"Sacubitril\/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial","volume":"25","author":"Chatur","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0173","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2020.08.014","article-title":"Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF","volume":"9","author":"Jering","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0174","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/ejhf.3223","article-title":"Effects of sacubitril\/valsartan according to polypharmacy status in PARAGON-HF","volume":"26","author":"Matsumoto","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0175","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1161\/CIRCULATIONAHA.124.068774","article-title":"Effect of sacubitril\/valsartan on cognitive function in patients with heart failure with preserved ejection fraction: A prespecified analysis of PARAGON-HF","volume":"150","author":"Dewan","year":"2024","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0176","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jchf.2022.01.018","article-title":"Atrial fibrillation in heart failure with preserved ejection fraction: The PARAGON-HF trial","volume":"10","author":"Cikes","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0177","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jchf.2021.01.011","article-title":"Burden of heart failure signs and symptoms, prognosis, and response to therapy: The PARAGON-HF trial","volume":"9","author":"Jering","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0178","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.cardfail.2023.02.001","article-title":"Rationale, design and baseline characteristics of the PARAGLIDE-HF trial: Sacubitril\/valsartan vs valsartan in HFmrEF and HFpEF with a worsening heart failure event","volume":"29","author":"Mentz","year":"2023","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0179","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0180","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","article-title":"Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: A pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF","volume":"44","author":"Vaduganathan","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0181","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ahj.2024.10.020","article-title":"Win ratio analyses using a modified hierarchical composite outcome: Insights from PARAGLIDE-HF","volume":"280","author":"Shoji","year":"2025","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0182","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ahj.2025.04.023","article-title":"Influence of ejection fraction on outcomes with sacubitril\/valsartan in patients with worsening heart failure with EF>40%: The PARAGLIDE-HF trial","volume":"289","author":"Peters","year":"2025","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0183","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.cardfail.2024.04.030","article-title":"Association of sacubitril\/valsartan vs valsartan with blood pressure changes and symptomatic hypotension: The PARAGLIDE-HF trial","volume":"30","author":"Fudim","year":"2024","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0184","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.cardfail.2024.05.003","volume":"30","author":"Hendren","year":"2024","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0185","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ahj.2025.03.017","article-title":"Effects of angiotensin-neprilysin inhibition in women vs men: Insights from PARAGLIDE-HF","volume":"288","author":"Rambarat","year":"2025","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0186","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ahj.2025.05.004","article-title":"Structural abnormalities and effects of sacubitril\/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: The PARAGLIDE-HF trial","volume":"289","author":"Kittipibul","year":"2025","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0187","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100984","article-title":"Effects of sacubitril\/valsartan vs valsartan in de novo vs acute on chronic HFpEF and HFmrEF","volume":"3","author":"Murray","year":"2024","journal-title":"JACC Adv"},{"key":"10.1053\/j.jvca.2025.12.003_bib0188","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/ejhf.3579","article-title":"Sacubitril\/valsartan versus valsartan initiation in patients naive to renin-angiotensin system inhibitors: Insights from PARAGLIDE-HF","volume":"27","author":"Nouhravesh","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0189","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.037899","article-title":"In-hospital or out-of-hospital initiation of sacubitril\/valsartan versus valsartan in patients with mildly reduced or preserved ejection fraction after a worsening heart failure event: The PARAGLIDE-HF trial","volume":"14","author":"Nouhravesh","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2025.12.003_bib0190","first-page":"528","article-title":"Positive recommendation for angiotensin receptor-neprilysin inhibitor: First medication approval for heart failure without reduced ejection fraction","volume":"37","author":"Howlett","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0191","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ahj.2017.12.021","article-title":"Rationale and methods of the prospective study of biomarkers, symptom improvement, and ventricular remodeling during sacubitril\/valsartan therapy for heart failure (PROVE-HF)","volume":"199","author":"Januzzi","year":"2018","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0192","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2025.12.003_bib0193","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jacc.2022.08.737","article-title":"Dose-response to sacubitril\/valsartan in patients with heart failure and reduced ejection fraction","volume":"80","author":"Mohebi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0194","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jchf.2022.07.001","article-title":"Age differences in effects of sacubitril\/valsartan on cardiac remodeling, biomarkers, and health status","volume":"10","author":"Murphy","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0195","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007829","article-title":"Racial and ethnic differences in biomarkers, health status, and cardiac remodeling in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan","volume":"13","author":"Ibrahim","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0196","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jchf.2020.09.014","article-title":"Reverse cardiac remodeling following initiation of sacubitril\/valsartan in patients with heart failure with and without diabetes","volume":"9","author":"Khan","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0197","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchf.2020.09.013","article-title":"Atrial natriuretic peptide and treatment with sacubitril\/valsartan in heart failure with reduced ejection fraction","volume":"9","author":"Murphy","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0198","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.cardfail.2023.10.001","article-title":"Isovolumic contraction velocity in heart failure with reduced ejection fraction and effect of sacubitril\/valsartan: The PROVE-HF study","volume":"30","author":"Omar","year":"2024","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0199","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/ejhf.2005","article-title":"Sex-based differences in biomarkers, health status, and reverse cardiac remodeling in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan","volume":"22","author":"Ibrahim","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0200","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006946","article-title":"Reverse cardiac remodeling and outcome after initiation of sacubitril\/valsartan","volume":"13","author":"Januzzi","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0201","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.121.054034","article-title":"Implantable cardioverter-defibrillator eligibility after initiation of sacubitril\/valsartan in chronic heart failure: Insights from PROVE-HF","volume":"144","author":"Felker","year":"2021","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0202","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jchf.2022.09.009","article-title":"Prediction of left ventricular ejection fraction change following treatment with sacubitril\/valsartan","volume":"11","author":"Mohebi","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0203","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1161\/CIRCULATIONAHA.122.061693","article-title":"Association between sacubitril\/valsartan initiation and mitral regurgitation severity in heart failure with reduced ejection fraction: The PROVE-HF study","volume":"146","author":"Januzzi","year":"2022","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0204","unstructured":"Dhont S, Ferreira SM, Galloo X, et al. Angiotensin receptor neprilysin inhibitor in heart failure with preserved ejection fraction and secondary mitral regurgitation: Design and rationale of the PRAISE-MR trial [published online June 23, 2025]. J Card Fail. 10.1016\/j.cardfail.2025.05.019."},{"key":"10.1053\/j.jvca.2025.12.003_bib0205","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13019-023-02252-y","article-title":"Benefits of sacubitril\/valsartan use in patients with chronic heart failure after cardiac valve surgery: A single-center retrospective study","volume":"18","author":"Zheng","year":"2023","journal-title":"J Cardiothorac Surg"},{"key":"10.1053\/j.jvca.2025.12.003_bib0206","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12435","article-title":"The reverse remodeling response to sacubitril\/valsartan therapy in heart failure with reduced ejection fraction","volume":"36","author":"Martens","year":"2018","journal-title":"Cardiovasc Ther"},{"key":"10.1053\/j.jvca.2025.12.003_bib0207","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.amjcard.2025.06.012","article-title":"Insights into the benefits of reverse remodeling from an echocardiographic pressure\/volume loop model in patients with heart failure treated with sacubitril\/valsartan","volume":"254","author":"Dini","year":"2025","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0208","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: A randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2025.12.003_bib0209","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jama.2019.12662","article-title":"Angiotensin receptor-neprilysin inhibition (ARNI) therapy and reverse remodeling in heart failure with reduced ejection fraction","volume":"322","author":"Drazner","year":"2019","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2025.12.003_bib0210","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11897-021-00501-6","article-title":"Reverse cardiac remodeling and ARNI therapy","volume":"18","author":"Abboud","year":"2021","journal-title":"Curr Heart Fail Rep"},{"key":"10.1053\/j.jvca.2025.12.003_bib0211","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007891","article-title":"Hemodynamic effects of sacubitril-valsartan versus enalapril in patients with heart failure in the EVALUATE-HF study: Effect modification by left ventricular ejection fraction and sex","volume":"14","author":"Mitchell","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0212","unstructured":"Lee S, Claggett BL, Fang JC, et al. Changes in cardiac structure and function are associated with health-related quality of life in heart failure with reduced ejection fraction: Results from the EVALUATE-HF trial [published online July 18, 2025]. Eur J Heart Fail. 10.1002\/ejhf.3760."},{"key":"10.1053\/j.jvca.2025.12.003_bib0213","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/ejhf.2541","article-title":"Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: The EVALUATE-HF trial","volume":"24","author":"Myhre","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0214","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jchf.2020.09.012","article-title":"Improvement of health status following initiation of sacubitril\/valsartan in heart failure and reduced ejection fraction","volume":"9","author":"Pina","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0215","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jchf.2021.09.007","article-title":"Early B-type natriuretic peptide change in HFrEF patients treated with sacubitril\/valsartan: A pooled analysis of EVALUATE-HF and PROVE-HF","volume":"10","author":"Myhre","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0216","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ehf2.12694","article-title":"Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: Design and rationale of the PARALLAX trial","volume":"7","author":"Wachter","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0217","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/ejhf.2277","article-title":"Baseline characteristics of patients in the PARALLAX trial: Insights into quality of life and exercise capacity in heart failure with preserved ejection fraction","volume":"23","author":"Shah","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0218","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of sacubitril\/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: The PARALLAX randomized clinical trial","volume":"326","author":"Piescke","year":"2021","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2025.12.003_bib0219","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/jcm8020262","article-title":"Early effects of sacubitril\/valsartan on exercise tolerance in patients with heart failure with reduced ejection fraction","volume":"8","author":"Vitale","year":"2019","journal-title":"J Clin Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0220","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/ejhf.2191","article-title":"Prospective ARNI vs. ACE inhibitor trial to determine superiority in reducing heart failure events after myocardial infarction (PARADISE-MI): Design and baseline characteristics","volume":"23","author":"Jering","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0221","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor-neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0222","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0223","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: A systemic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2025.12.003_bib0224","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/ejhf.2663","article-title":"Sacubitril\/valsartan versus ramipril for patients with acute myocardial infarction: Win-ratio analysis of the PARADISE-MI trial","volume":"24","author":"Berwanger","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0225","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.122.059210","article-title":"Impact of sacubitril\/valsartan compared with ramipril on cardiac structure and function after acute myocardial infarction: The PARADISE-MI echocardiographic substudy","volume":"146","author":"Shah","year":"2022","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0226","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/ejhf.3472","article-title":"Sex differences in cardiac structure and function following acute myocardial infarction: Insights from the PARADISE-MI echocardiography substudy","volume":"27","author":"Wang","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0227","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1161\/CIRCULATIONAHA.122.060841","article-title":"The effects of angiotensin receptor-neprilysin inhibition on major coronary events in patients with acute myocardial infarction: Insights from the PARADISE-MI trial","volume":"146","author":"Mehran","year":"2022","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0228","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.62347\/NUKJ1589","article-title":"Early initiation of sacubitril\/valsartan in STEMI patients improves ventricular remodeling","volume":"17","author":"Wang","year":"2025","journal-title":"Am J Transl Res"},{"key":"10.1053\/j.jvca.2025.12.003_bib0229","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028942","article-title":"Sex differences in clinical characteristics and outcomes after myocardial infarction with low ejection fraction: Insights from PARADISE-MI","volume":"12","author":"Wang","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2025.12.003_bib0230","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.amjcard.2025.07.032","article-title":"Differences in characteristics and clinical outcomes according to age in patients following high-risk myocardial infarction: Insights from PARADISE-MI","volume":"257","author":"Jering","year":"2025","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0231","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/ejhf.3542","article-title":"Association between body mass index and clinical outcomes in patients with acute myocardial infarction and reduced systolic function: Analysis of PARADISE-MI trial data","volume":"27","author":"Amir","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0232","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/ejhf.2851","article-title":"Geographic differences in patients with acute myocardial infarction in the PARADISE-MI trial","volume":"25","author":"Butt","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0233","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jacc.2024.01.002","article-title":"Angiotensin receptor-neprilysin inhibition in patients with STEMI vs NSTEMI","volume":"83","author":"Mann","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0234","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/CIRCULATIONAHA.123.066163","article-title":"Pulmonary congestion and left ventricular dysfunction after myocardial infarction: Insights from the PARADISE-MI trial","volume":"149","author":"Petrie","year":"2024","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0235","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011393","article-title":"Safety and tolerability of angiotensin receptor-neprilysin inhibitor initiation in high-risk acute myocardial infarction relative to care setting: A subgroup analysis of the PARADISE-MI trial","volume":"17","author":"De Pasquale","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0236","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/ejhf.3386","article-title":"Acute changes in kidney function and outcomes following an acute myocardial infarction: Insights from PARADISE-MI","volume":"26","author":"McCausland","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0237","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.010259","article-title":"Prognostic importance of NT-proBNP (N-terminal pro-B-type natriuretic peptide) following high-risk myocardial infarction in the PARADISE-MI trial","volume":"16","author":"Jering","year":"2023","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0238","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ejhf.3079","article-title":"Sacubitril\/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial","volume":"26","author":"Schou","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0239","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ahj.2017.07.006","article-title":"Design for the sacubitril\/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF)","volume":"193","author":"Shaddy","year":"2017","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2025.12.003_bib0240","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.009816","article-title":"Baseline characteristics of pediatric patients with heart failure due to systemic left ventricular systolic dysfunction in the PANORAMA-HF trial","volume":"16","author":"Shaddy","year":"2023","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0241","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1161\/CIRCULATIONAHA.123.066605","article-title":"Sacubitril\/valsartan in pediatric heart failure (PANORAMA-HF): A randomized, multicenter, double-blind trial","volume":"150","author":"Shaddy","year":"2024","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0242","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.healun.2024.01.012","article-title":"Sacubitril-valsartan vs ACE\/ARB in pediatric heart failure: A retrospective cohort study","volume":"43","author":"Hale","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"10.1053\/j.jvca.2025.12.003_bib0243","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1002\/ehf2.15326","article-title":"Association between NT-proBNP changes and clinical outcomes in paediatric patients with heart failure: Insights from PANORAMA-HF and PARADIGM-HF","volume":"12","author":"Shaddy","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0244","first-page":"33","article-title":"Rationale and design of the prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA II) trial: A randomized, placebo-controlled, multicenter trial","volume":"7","author":"Mecinaj","year":"2021","journal-title":"Cardiooncology"},{"key":"10.1053\/j.jvca.2025.12.003_bib0245","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1161\/CIRCULATIONAHA.125.076616","article-title":"Sacubitril-valsartan and prevention of cardiac dysfunction during adjuvant breast cancer therapy: The PRADA-II randomized clinical trial","volume":"152","author":"Omland","year":"2025","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.12.003_bib0246","unstructured":"Hsu YL, Lee CH, Chung WP, et al. Primary cardioprotective effect of sacubitril\/valsartan in breast cancer patients receiving adjuvant therapy [published online July 10, 2025]. Eur J Heart Fail. 10.1002\/ejhf.3758."},{"key":"10.1053\/j.jvca.2025.12.003_bib0247","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101628","article-title":"Effect of sacubitril\/valsartan or enalapril on left ventricular function in patients with hematological malignancies treated with bone marrow transplantation: A randomized controlled trial","volume":"4","author":"Katogiannis","year":"2025","journal-title":"JACC Adv"},{"key":"10.1053\/j.jvca.2025.12.003_bib0248","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ehf2.12610","article-title":"Sacubitril\/valsartan in patients listed for heart transplantation: Effect on physical frailty","volume":"7","author":"Cacciatore","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0249","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.3390\/jcm14082539","article-title":"Sacubitril\/valsartan improves hemodynamic parameters of pulmonary and systemic circulation in patients awaiting heart transplantation","volume":"14","author":"Raduly","year":"2025","journal-title":"J Clin Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0250","unstructured":"Cikes M, Planinc I, Brugts JJ, et al. Rationale, design, and baseline characteristics of the multicenter, randomized, open-label, parallel group, study to evaluate the use of sacubitril\/valsartan in HeartMate 3 left ventricular assist device recipients (ENVAD-HF) [published online August 14, 2025]. J Card Fail. 10.1016\/j.cardfail.2025.07.015."},{"key":"10.1053\/j.jvca.2025.12.003_bib0251","article-title":"Angiotensin-neprilysin inhibition and left ventricular assist device therapy\u2014Primary results of the multicenter, randomized, open-label, parallel group, study to evaluate the use of sacubitril\/valsartan in HeartMate 3 LVAD recipients (ENVAD-HF)","volume":"13","author":"Cikes","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0252","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ejhf.3072","article-title":"Short-term effects of sacubitril\/valsartan therapy on myocardial oxygen consumption and energetic efficiency of cardiac work in heart failure with reduced ejection fraction: A randomized controlled trial","volume":"26","author":"Nesterov","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0253","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jchf.2024.05.021","article-title":"Sacubitril\/valsartan versus enalapril in chronic Chagas cardiomyopathy: Rationale and design of the PARACHUTE-HF trial","volume":"12","author":"Bocchi","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0254","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1002\/ejhf.3460","article-title":"Mechanisms behind the high mortality rate in chronic Chagas cardiomyopathy: Unmasking a three-headed monster","volume":"26","author":"Echeverria","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.12.003_bib0255","unstructured":"Echeverria LE, Bocchi E, Demacq C, et al. Sacubitril\/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial [published online September 8, 2025]. Eur J Heart Fail. 10.1002\/ejhf.70026."},{"key":"10.1053\/j.jvca.2025.12.003_bib0256","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033538","article-title":"Angiotensin receptor-neprilysin inhibitor is associated the improved cardiac autonomic function in heart failure","volume":"13","author":"Boehmer","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2025.12.003_bib0257","unstructured":"Li W, Feng W, Wang J, et al. The FUNCTION study: A randomized controlled trial on the efficacy of sacubitril\/valsartan on the success rate of catheter ablation for nonparoxysmal atrial fibrillation [published online May 7, 2025]. Cardiovasc Drugs Ther. 10.1007\/s10557-025-07706-0."},{"key":"10.1053\/j.jvca.2025.12.003_bib0258","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200141","article-title":"Low-voltage myocardium-guided ablation trial of persistent atrial fibrillation","volume":"1","author":"Huo","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1053\/j.jvca.2025.12.003_bib0259","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.hroo.2021.09.009","article-title":"Sacubitril\/valsartan versus angiotensin inhibitors and arrhythmia endpoints in heart failure with reduced ejection fraction","volume":"2","author":"Fernandes","year":"2021","journal-title":"Heart Rhythm O2"},{"key":"10.1053\/j.jvca.2025.12.003_bib0260","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jamacardio.2023.0065","article-title":"Effect of sacubitril\/valsartan vs valsartan on left atrial volume in patients with pre-heart failure with preserved ejection fraction: The PARABLE randomized controlled trial","volume":"8","author":"Ledwidge","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0261","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12933-025-02741-5","article-title":"Sacubitril\/valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: An opportunity to prevent progressive disease","volume":"24","author":"Karuna","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2025.12.003_bib0262","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1248468","article-title":"Sacubitril\/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: A prospective, randomized, open-label, blinded endpoint clinical trial protocol","volume":"10","author":"Lee","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0263","doi-asserted-by":"crossref","first-page":"6981","DOI":"10.1038\/s41467-025-62203-0","article-title":"Effects of sacubitril\/valsartan on hypertensive heart disease: The REVERSE-LVH randomized phase 2 trial","volume":"16","author":"Lee","year":"2025","journal-title":"Nat Commun"},{"key":"10.1053\/j.jvca.2025.12.003_bib0264","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00000542-199408000-00006","article-title":"Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction","volume":"81","author":"Coriat","year":"1994","journal-title":"Anesthesiology"},{"key":"10.1053\/j.jvca.2025.12.003_bib0265","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1097\/00000539-199912000-00011","article-title":"The hemodynamic effects of anesthetic induction in vascular surgical patients chronically treated with angiotensin II receptor antagonists","volume":"89","author":"Brabant","year":"1999","journal-title":"Anesth Analg"},{"key":"10.1053\/j.jvca.2025.12.003_bib0266","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.jvca.2007.12.020","article-title":"Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery","volume":"22","author":"Kheterpal","year":"2008","journal-title":"J Cardiothoracic Vasc Anesth"},{"key":"10.1053\/j.jvca.2025.12.003_bib0267","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00000542-200501000-00006","article-title":"Terlipressin versus norepinephrine to counteract anesthesia-induced hypotension in patients treated with renin-angiotensin system inhibitors: Effects on systemic and regional hemodynamics","volume":"102","author":"Morelli","year":"2005","journal-title":"Anesthesiology"},{"key":"10.1053\/j.jvca.2025.12.003_bib0268","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00000542-200609000-00026","article-title":"The vasopressin system: Physiology and clinical strategies","volume":"105","author":"Treschan","year":"2006","journal-title":"Anesthesiology"},{"key":"10.1053\/j.jvca.2025.12.003_bib0269","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00000539-200101000-00006","article-title":"Should the angiotensin II antagonists be discontinued before surgery?","volume":"92","author":"Bertrand","year":"2001","journal-title":"Anesth Analg"},{"key":"10.1053\/j.jvca.2025.12.003_bib0270","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009917","article-title":"Comparison of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker management strategies before cardiac surgery: A pilot randomized controlled registry trial","volume":"7","author":"van Diepen","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2025.12.003_bib0271","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3949\/ccjm.92a.25035","article-title":"Hold ACE inhibitors and ARBs before noncardiac surgery? Emerging evidence suggests a patient-specific approach","volume":"92","author":"Keshock","year":"2025","journal-title":"Cleve Clin J Med"},{"key":"10.1053\/j.jvca.2025.12.003_bib0272","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1053\/j.jvca.2025.06.015","article-title":"Advances in cardiovascular pharmacotherapy. IV. Sodium-glucose cotransporter type 2 inhibitors, part 2: Mechanisms for myocardial protection, adverse effects, and perioperative implications","volume":"39","author":"Pagel","year":"2025","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2025.12.003_bib0273","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.123.065748","article-title":"Blinded withdrawal of long-term randomized treatment with empagliflozin or placebo in patients with heart failure","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077025012042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077025012042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:52:03Z","timestamp":1771408323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077025012042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":273,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1053077025012042"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2025.12.003","relation":{},"ISSN":["1053-0770"],"issn-type":[{"value":"1053-0770","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Cardiovascular Pharmacotherapy. VI. Sacubitril-Valsartan, An Angiotensin Receptor-Neprilysin Inhibitor","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}